SCHEMBL7128747

SCHEMBL7128747

Cc1ncc(-c2cccc(NC(=S)NCc3ccccn3)c2)n1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.64
CYP3A4 P08684 2/20 0.64
CYP2C19 P33261 2/20 0.64
ALDH1A1 P00352 8/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
RAB9A P51151 3/20 0.58
MAPT P10636 3/20 0.58
HPGD P15428 2/20 0.58
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
GAA P10253 2/20 0.48
KDM4E B2RXH2 1/20 0.48
GLA P06280 1/20 0.48
QPCT Q16769 1/20 0.48
LMNA P02545 2/20 0.47
NPC1 O15118 1/20 0.47
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7121296 0.77 CYP1A2 (0.50) CYP1A2ALDH1A1KMT2AKDM4E
SCHEMBL7125607 0.76 ALDH1A1 (0.47) CYP1A2CYP3A4CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL7125139 0.75 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2RAB9AMAPTHPGD
SCHEMBL11190896 0.74 ALDH1A1 (0.78) CYP1A2CYP3A4CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL11647735 0.74 ALDH1A1 (1.00) CYP1A2CYP3A4CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL7984129 0.72 FGFR3 (0.42)
SCHEMBL11646615 0.71 ALDH1A1 (1.00) CYP1A2CYP3A4CYP2C19ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL7123999 0.71 FGFR3 (0.41)
SCHEMBL11719425 0.70 ALDH1A1 (0.70) CYP1A2CYP3A4CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL7125057 0.70 ALDH1A1 (0.68) CYP1A2CYP3A4CYP2C19ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 CYP1A2 25/4885CYP3A4 182/4885CYP2C19 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.